Summary of phase II/III double-blind, placebo-controlled trials evaluating onartuzumab in patients with solid tumors.
收藏Figshare2015-12-03 更新2026-04-29 收录
下载链接：
https://figshare.com/articles/dataset/_Summary_of_phase_II_III_double_blind_placebo_controlled_trials_evaluating_onartuzumab_in_patients_with_solid_tumors_/1567033
下载链接
链接失效反馈官方服务：
资源简介：
Bev = bevacizumab, Erl = erlotinib, FOLFOX = oxaliplatin, 5-fluorouracil and folinic acid, GBM = glioblastoma, mCRC = metastatic colorectal cancer, NSCLC = non-small cell lung cancer, Ona = onartuzumab, Pac = paclitaxel, Pbo = placebo, Pem = pemetrexed, Plat = carboplatin or cisplatin, TNBC = triple negative metastatic breast cancer. Data cut-off dates: GO27819: 7 Nov 2013; GO27820: 9 January 2014; GO27821 (Cohort 1): 31 October 2013; GO27821 (Cohort 2): 9 September 2013; GO27827: 6 Feb 2014; OAM4861g: 22 March 2014; OAM4971g: 26 October 2013; YO28252: 29 Jan 2014.Summary of phase II/III double-blind, placebo-controlled trials evaluating onartuzumab in patients with solid tumors.
创建时间：
2015-12-03
